1. Market Research
  2. > Pharmaceutical
  3. > Pathology Market Trends
  4. > MarketVIEW: Candida vaccines

MarketVIEW: Candida vaccines

  • July 2012
  • -
  • VacZine Analytics Group Of Assay Advantage Ltd

Candida yeasts cause Candidiasis which is a fungal infection commonly found in humans. Infections can occur in the female Genital area "vulvovaginal candidiasis" of which nearly 75% of all adult women have had one "yeast infection" in their lifetime. Some women experience recurrent episodes (RVVC) which can cause considerable inconvenience and distress. Invasive Candidiasis, is a life threatening infection which mainly affects individuals with serious underlying co-morbidities. Infections usually occur in the hospital intensive care unit (ICU) where it is the fourth most common bloodstream infection (CDC Figures).

This MarketVIEW This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Candida vaccines across major Western markets until 2030. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates for both Recurrent Vulvovaginal Candidiasis (RVVC) and invasive Candidiasis (in the ICU setting) indications. For RVVC indication 3 prevalence scenarios (LO/MID/HI) are included. The product also includes an up-to-date review of latest competitor activity in the field and Candida epidemiology.

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL

Table Of Contents

MarketVIEW: Candida vaccines
Executive Summary
RVVC TX vaccine: available market ($000s) to 2030, realistic RVVC
prevalence
RVVC TX vaccine: available market ($000s) to 2030 by conservative,
realistic and optimistic RVVC prevalence
RVVC TX vaccine: available market (000s doses) to 2030
Candida ICU PX vaccine: available market ($000s) to 2030
Candida ICU PX vaccine: available market (000s doses) to 2030
The role of Candida vaccines
Candida ICU PX vaccine: target product profile
RVVC TX vaccine: target product profile
Candida ICU PX vaccine: model assumptions
RVVC TX vaccine: model assumptions
Key commercial model assumptions
Pricing
Competitor landscape: overview
Pevion (PEV7)
NovaDigm Therapeutics (NDV-3)
Vulvovaginal candidiasis: overview
Vulvovaginal candidiasis: surveillance
Vulvovaginal candidiasis: regional data
Vulvovaginal candidiasis: primary care consultations
Vulvovaginal candidiasis: drug utilization
Vulvovaginal candidiasis: drug utilization
Vulvovaginal candidiasis: population based studies
Vulvovaginal candidiasis: incidence/prevalence summary
Invasive candidiasis: overview
Invasive candidiasis: national surveillance data
Invasive candidiasis: estimating ICU admissions
Bibliography
Disclaimer
About VacZine Analytics

PAGES: 50 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents - Vaccine demand model (MS Excel-based)

Title
Scenarios
Charts value (RVVC)
Charts value (ICU)
Charts volume (RVVC and ICU)
Value summary (ICU)
Volume summary (ICU)
Value summary (RVVC)
Volume summary (RVVC)
Model inputs (RVVC)
ICU patients =>
US (ICU)
UK (ICU)
CANADA (ICU)
GERMANY (ICU)
SPAIN (ICU)
FRANCE (ICU)
ITALY (ICU)
EU other (ICU)
AUSTRALIA (ICU)
JAPAN (ICU)
RVVC patients =>
LO/BASE/HI prevalence scenarios
US (RVVC)
UK (RVVC)
CANADA (RVVC)
GERMANY (RVVC)
SPAIN (RVVC)
FRANCE (RVVC)
ITALY (RVVC)
EU other (RVVC)
AUSTRALIA (RVVC)
JAPAN (RVVC)
Source material
ICU database
RVVC database
UK RVVC epi
US ICU epi
Back page

Worksheets = >60 interconnected

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Clare

+1 718 303 2384

Purchase Reports From Reputable Market Research Publishers

Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2015

Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2015

  • $ 2 995
  • Industry report
  • June 2015
  • by Currentpartnering

The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2015 report provides comprehensive understanding and unprecedented access to the asset purchase agreements entered into by the worlds ...

Cancer Vaccines Drug Pipeline Update 2015

Cancer Vaccines Drug Pipeline Update 2015

  • $ 3 139
  • Industry report
  • June 2015
  • by Bioseeker

Cancer vaccines offer an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. However, despite years of R&D, a reproducible survival benefit has ...

Human Papillomavirus Infections Global Clinical Trials Review, H1, 2015

Human Papillomavirus Infections Global Clinical Trials Review, H1, 2015

  • $ 2 500
  • Industry report
  • June 2015
  • by Global Data

Human Papillomavirus Infections Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Human Papillomavirus Infections Global Clinical Trials Review, H1, 2015" provides ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.